Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations

Martin Neumann, Sandra Heesch, Cornelia Schlee, Stefan Schwartz, Nicola Gökbuget, Dieter Hoelzer, Nikola P. Konstandin, Bianka Ksienzyk, Sebastian Vosberg, Alexander Graf, Stefan Krebs, Helmut Blum, Thorsten Raff, Monika Brüggemann, Wolf-Karsten Hofmann, Jochen Hecht, Stefan K. Bohlander, Philipp A. Greif, Claudia D. Baldus

Blood (2013) 121 (23): 4749–4752.

https://doi.org/10.1182/blood-2012-11-465138

Published: 2013

Includes: Supplemental data

Journal Articles

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Blood (2012) 120 (26): 5185–5187.

https://doi.org/10.1182/blood-2012-07-441030

Published: 2012

Journal Articles

Has MRD monitoring superseded other prognostic factors in adult ALL?

Monika Brüggemann, Thorsten Raff, Michael Kneba

Blood (2012) 120 (23): 4470–4481.

https://doi.org/10.1182/blood-2012-06-379040

Published: 2012

Journal Articles

Exome Sequencing Identifies Recurring DNMT3A Mutations in Adult ETP-ALL

Martin Neumann, MD, Sandra Heesch, PhD, Cornelia Schlee, MS, Stefan Schwartz, MD, Nicola Goekbuget, MD, Dieter Hoelzer, MD, Nikola P Konstandin, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Thorsten Raff, MD, Monika Brueggemann, Wolf-Karsten Hofmann, Stefan K Bohlander, MD, Philipp A Greif, MD, Claudia D Baldus

Blood (2012) 120 (21): 1377.

https://doi.org/10.1182/blood.V120.21.1377.1377

Published: 2012

Journal Articles

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

Nicola Gökbuget, Michael Kneba, Thorsten Raff, Heiko Trautmann, Claus-Rainer Bartram, Renate Arnold, Rainer Fietkau, Mathias Freund, Arnold Ganser, Wolf-Dieter Ludwig, Georg Maschmeyer, Harald Rieder, Stefan Schwartz, Hubert Serve, Eckhard Thiel, Monika Brüggemann, Dieter Hoelzer

Blood (2012) 120 (9): 1868–1876.

https://doi.org/10.1182/blood-2011-09-377713

Published: 2012

Includes: Supplemental data

Journal Articles

Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse

Nicola Goekbuget, MD, Daniel Stanze, MD, Renate Arnold, Monika Brueggemann, MD, Rainer Fietkau, MD, Mathias Freund, MD, Arnold Ganser, MD, Wolf-Dieter Ludwig, Georg Maschmeyer, MD, Thorsten Raff, MD, Harald Rieder, MD, Eckhard Thiel, Hubert Serve, MD, Michael Kneba, MD, Dieter Hoelzer, MD

Blood (2011) 118 (21): 250.

https://doi.org/10.1182/blood.V118.21.250.250

Published: 2011

Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 174.

https://doi.org/10.1182/blood.V116.21.174.174

Published: 2010

Journal Articles

Multidrug resistance–associated protein 4 ( MRP4 ) gene polymorphisms and treatment response in adult acute lymphoblastic leukemia

Monika Brüggemann, Heiko Trautmann, Dieter Hoelzer, Michael Kneba, Nicola Gökbuget, Thorsten Raff

Blood (2009) 114 (26): 5400–5401.

https://doi.org/10.1182/blood-2009-09-243741

Published: 2009

Journal Articles

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 840.

https://doi.org/10.1182/blood.V114.22.840.840

Published: 2009

Journal Articles

New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).

Nicola Goekbuget, MD, Monika Brueggemann, MD, Renate Arnold, MD, Claus-Rainer Bartram, PhD, Rainer Fietkau, MD, Mathias Freund, MD, Arnold Ganser, MD, Michael Kneba, MD, PhD, Thomas Lipp, MD, Wolf-Dieter Ludwig, MD, Georg Maschmeyer, MD, Dorle Messerer, Thorsten Raff, MD, Harald Rieder, MD, Eckhard Thiel, Dieter Hoelzer, MD, PhD

Blood (2009) 114 (22): 90.

https://doi.org/10.1182/blood.V114.22.90.90

Published: 2009

Journal Articles

Insight Into HCDR3 Restrictions in CLL by Analysis of Incomplete IGHD-IGHJ Rearrangements: Further Evidence that Somatic Selection Shapes the Expressed CLL Immunoglobulin Repertoire.

Eugenia Tsakou, Andreas Agathagelidis, Myriam Boudjoghra, Thorsten Raff, Antonis Dagklis, Georgios Bourikas, Helene Merle-Beral, Achilles Anagnostopoulos, Nikolaos Laoutaris, Monika Bruggemann, Frederic Davi, Kostas Stamatopoulos, Chrysoula Belessi

Blood (2009) 114 (22): 2346.

https://doi.org/10.1182/blood.V114.22.2346.2346

Published: 2009

Journal Articles

The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group

Thomas Burmeister, Claus Meyer, Stefan Schwartz, Julia Hofmann, Mara Molkentin, Eric Kowarz, Björn Schneider, Thorsten Raff, Richard Reinhardt, Nicola Gökbuget, Dieter Hoelzer, Eckhard Thiel, Rolf Marschalek

Blood (2009) 113 (17): 4011–4015.

https://doi.org/10.1182/blood-2008-10-183483

Published: 2009

Journal Articles

Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial

Sebastian Boettcher, MD, Stephan Stilgenbauer, MD, PhD, Raymonde Busch, Monika Brüggemann, MD, PhD, Thorsten Raff, MD, Kirsten Fischer, MD, Günter Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Christiane Pott, MD, Hartmut Döhner, MD, PhD, Michael Hallek, MD, PhD, Michael Kneba, MD, PhD, Matthias Ritgen, MD, on Behalf Of GCLLSG

Blood (2008) 112 (11): 3139.

https://doi.org/10.1182/blood.V112.11.3139.3139

Published: 2008

Journal Articles

Emergence of Dominant T-Cell Populations in Patients with CLL after Allogeneic Transplantation: Mediators for Gvl Effects?

Matthias Ritgen, MD, Monika Brueggemann, MD, PhD, Sebastian Boettcher, MD, Thorsten Raff, MD, Christiane Pott, MD, Michael Hallek, M.D., Michael Kneba, MD, PhD, Peter Dreger, MD

Blood (2008) 112 (11): 3503.

https://doi.org/10.1182/blood.V112.11.3503.3503

Published: 2008

Journal Articles

MRD Kinetics in Adult Transplantation Recipients with Relapsed Acute Lymphoblastic Leukemia Depend on Initial Molecular Response to Front-Line Chemotherapy.

Monika Brüggemann, MD, Thorsten Raff, MD, Christiane Pott, MD, Sebastian Böttcher, MD, Matthias Ritgen, MD, Renate Arnold, MD, Dieter Hoelzer, MD, Nicola Goekbuget, MD, Michael Kneba, MD

Blood (2007) 110 (11): 2799.

https://doi.org/10.1182/blood.V110.11.2799.2799

Published: 2007

Journal Articles

Quantitative Assessment of Circulating t(14;18) Positive Cells by RQ-PCR at Diagnosis and Follow-Up Correspond to Clinical Characteristics and Predicts Time to Treatment Failure in Follicular Lymphoma.

Christiane Pott, MD, Sebastian Boettcher, MD, Monika Brueggemann, MD, Thorsten Raff, MD, Matthias Ritgen, MD, Michael Unterhalt, MD, Martin Dreyling, MD, Wolfgang Hiddemann, MD, Eva Hoster, MS, Michael Kneba, MD

Blood (2006) 108 (11): 2414.

https://doi.org/10.1182/blood.V108.11.2414.2414

Published: 2006

Journal Articles

Sensitivity and Applicability of Six-Color Flow Cytometry Is Comparable to ASO-Primer-Real-Time PCR (RQ-PCR) for Minimal Residual Disease (MRD) Monitoring in Adult Acute Lymphoblastic Leukemia (ALL) - A Comparative Analysis in 70 Patients from the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL).

Sebastian Boettcher, MD, Sebastian Irmer, MD, Silke Lueschen, PhD, Matthias Ritgen, MD, Thorsten Raff, MD, Nicola Goekbuget, MD, Dieter Hoelzer, MD, Heinz-August Horst, MD, Michael Kneba, MD, PhD, Monika Brueggemann, MD

Blood (2006) 108 (11): 2287.

https://doi.org/10.1182/blood.V108.11.2287.2287

Published: 2006

Journal Articles

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

Thorsten Raff, Nicola Gökbuget, Silke Lüschen, Regina Reutzel, Matthias Ritgen, Sebastian Irmer, Sebastian Böttcher, Heinz-August Horst, Michael Kneba, Dieter Hoelzer, Monika Brüggemann, for the GMALL Study Group

Blood (2006) 109 (3): 910–915.

https://doi.org/10.1182/blood-2006-07-037093

Published: 2006

Journal Articles

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma

Christiane Pott, Carsten Schrader, Stefan Gesk, Lana Harder, Markus Tiemann, Thorsten Raff, Monika Brüggemann, Matthias Ritgen, Benedikt Gahn, Michael Unterhalt, Martin Dreyling, Wolfgang Hiddemann, Reiner Siebert, Peter Dreger, Michael Kneba

Blood (2006) 107 (6): 2271–2278.

https://doi.org/10.1182/blood-2005-07-2845

Published: 2006

Journal Articles

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Monika Brüggemann, Thorsten Raff, Thomas Flohr, Nicola Gökbuget, Makoto Nakao, Jo Droese, Silke Lüschen, Christiane Pott, Matthias Ritgen, Urban Scheuring, Heinz-August Horst, Eckhard Thiel, Dieter Hoelzer, Claus R. Bartram, Michael Kneba, for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia

Blood (2006) 107 (3): 1116–1123.

https://doi.org/10.1182/blood-2005-07-2708

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Has MRD monitoring superseded other prognostic factors in adult ALL?

Exome Sequencing Identifies Recurring DNMT3A Mutations in Adult ETP-ALL

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Multidrug resistance–associated protein 4 ( MRP4 ) gene polymorphisms and treatment response in adult acute lymphoblastic leukemia

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).

Insight Into HCDR3 Restrictions in CLL by Analysis of Incomplete IGHD-IGHJ Rearrangements: Further Evidence that Somatic Selection Shapes the Expressed CLL Immunoglobulin Repertoire.

The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group

Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial

Emergence of Dominant T-Cell Populations in Patients with CLL after Allogeneic Transplantation: Mediators for Gvl Effects?

MRD Kinetics in Adult Transplantation Recipients with Relapsed Acute Lymphoblastic Leukemia Depend on Initial Molecular Response to Front-Line Chemotherapy.

Quantitative Assessment of Circulating t(14;18) Positive Cells by RQ-PCR at Diagnosis and Follow-Up Correspond to Clinical Characteristics and Predicts Time to Treatment Failure in Follicular Lymphoma.

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only